Study of YH004 (4-1BB Agonist Antibody) in Advanced or Metastatic Malignancy

Summary

YH004 is a humanized monoclonal antibody that specifically binds to 4-1BB, and acts as an agonist against 4-1BB. This first in human study of YH004 is designed to establish the maximum tolerated dose (MTD) and/or the recommended Phase II dose (RP2D) of YH004, both as a single agent (monotherapy) and in combination with a fixed dose of anti-PD-1 antibody (Toripalimab) in the treatment of advanced solid tumors and relapsed or refractory non-Hodgkin Lymphoma.

Timeline

Start

2021-12-07

Primary completion

2023-07-16

Completion

2023-07-16

Drugs

Indications